Document is current
Any future updates will be listed below
-
Authors
Huang, Daniel Q. http://orcid.org/0000-0002-5165-5061
El-Serag, Hashem B. http://orcid.org/0000-0001-5964-7579
Loomba, Rohit http://orcid.org/0000-0002-4845-9991
- License Information
-
More Information
Article History
Accepted: 23 October 2020
First Online: 21 December 2020
Competing interests
: R.L. serves as a consultant or advisory board member for Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Inipharm, Intercept, Ionis, Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Promethera, Sagimet, 89 bio, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer Ingelheim, Bristol Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer, pH Pharma, and Siemens. He is also co-founder of Liponexus, Inc.
